An interventional study of Diamine Oxidase (DAO) and Placebo in Histamine Intolerance, Food Hypersensitivity and Histamine Sensitivity, sponsored by DR Healthcare - biotexia. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by DR Healthcare - biotexia · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Food Hypersensitivity with a site in Spain — 8 open to participants now, 10 under way, 3 of them phase 3. Food Hypersensitivity · Spain.
Among the 23 studies in Food Hypersensitivity with a site in Spain, this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 23rd registered.
378 studies on the registry are indexed under Food Hypersensitivity; 92 are open to participants now.
Browse Food Hypersensitivity studies →8 of the 23 studies in Food Hypersensitivity with a site in Spain are open now. Recruiting first, the newest first:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Sites in Spain
Ages 4–17
University of Valencia · Sites in Spain
Ages 12–16 · Healthy volunteers
Pablo Rodríguez del Rio · Sites in Spain
Ages 6–16
Outcomes'10 · Sites in Spain
Ages up to 10 mo
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Sites in Spain
Ages 18–60
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 54 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 42 (78%) stop at 75 or younger; 46 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 2
First in 2015; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 68 across the 19 interventional studies, 41 across the 3 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
DR Healthcare - biotexia is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
DR Healthcare - biotexia has 1 study filed under Food Hypersensitivity — fewer than ten, so there is no comparison to draw.
7 of the studies in Food Hypersensitivity with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT06976775Phase 3Pablo Rodríguez del RioComparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study | 2027-04-30 |
| NCT06558526Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients | 2026-11-30 |
| NCT06997432Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludEndophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy | 2026-12 |
| NCT07934953DR Healthcare - biotexiaEffect of Oral Diamine Oxidase on Symptoms Induced by Histamine Oral Challenge | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 23 studies in Food Hypersensitivity with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether oral diamine oxidase (DAO) can lower symptoms caused by an oral histamine challenge in adults with self-reported food-related histamine symptoms who demonstrate responsiveness to histamine challenge during screening.
Histamine intolerance is characterized by the occurrence of symptoms after ingestion of histamine-containing foods and may be associated with reduced degradation of dietary histamine by the enzyme diamine oxidase (DAO). Previous studies have suggested potential benefits of oral DAO supplementation; however, additional controlled clinical studies are needed using standardized histamine challenge procedures and predefined symptom assessments.
This study is a randomized, double-blind, placebo-controlled, crossover trial conducted in healthy adult volunteers who demonstrate a predefined response to histamine provocation are randomized into the treatment phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Diamine Oxidase (DAO)
Placebo
Dietary Supplement: Placebo
Oral diamine oxidase (DAO) dietary supplement administered before a standardized oral histamine challenge in a randomized, double-blind, crossover study.
Matching placebo capsule administered before a standardized oral histamine challenge in a randomized, double-blind, crossover study.
Overall symptom burden following oral histamine challenge
Overall symptom burden is assessed using a study-specific symptom rating scale covering three domains: gastrointestinal, cutaneous/mucosal, and headache/neurovegetative symptoms. Each domain is rated from 0 (no symptoms) to 10 (maximum imaginable symptom intensity), resulting in a total score ranging from 0 to 30, with higher scores indicating greater symptom burden. The primary outcome is the area under the curve (AUC) of the total symptom score over the first 4 hours following the histamine challenge.
Time frame: 0 to 4 hours after histamine challenge
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Feb 2027, 5 months after the start.
Of 85 interventional studies with no phase under Food Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DR Healthcare - biotexia